Q-omics provides the consensus-scored ZNF880 profile across patient tissues and cancer cell-line models. ZNF880 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ZNF880 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, ZNF880 RNA expression shows 19,336 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, and THYM as cancer lineages where ZNF880 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF880 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF880 survival associations across molecular data types. ZNF880 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF880 RNA expression–survival associations across cancer types. High ZNF880 expression shows unfavorable associations in MESO and LUAD, but favorable associations in HNSC, KIRC, SCLC and UCS. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ZNF880 RNA expression.
This table summarizes ZNF880 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF880. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF880 shows lower tumor expression in HNSC, KICH, KIRC, LUSC and COAD and higher tumor expression in CHOL. The HNSC box plot shows higher ZNF880 RNA expression in normal versus tumor tissue (log2 FC = −0.877, t-test p < 0.001).
This table shows molecular features associated with ZNF880 in patient tissues and cancer cell lines. In patient samples, ZNF880 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF880 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
